menu
    • menu

    Company profile for Aprea Therapeutics

    NEW Drugs in Dev: 7
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aprea Therapeutics is a Stockholm, Sweden and Boston, Massachusetts-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein, p53. The Company’s lead program, APR-246, a first-in-class small molecule drug candidate, is in Phase Ib/II clinical development in ovarian cancer patients, and additional clinical studies with APR-246 in other can...
    Aprea Therapeutics is a Stockholm, Sweden and Boston, Massachusetts-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein, p53. The Company’s lead program, APR-246, a first-in-class small molecule drug candidate, is in Phase Ib/II clinical development in ovarian cancer patients, and additional clinical studies with APR-246 in other cancer indications are planned. In March 2016, Aprea completed a EUR 46 million Series B financing with an international syndicate co-led by Versant Ventures and 5AM Ventures.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aprea TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    535 Boylston St. Boston, MA 02116 USA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aprea.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    ChemTides

    Not Confirmed

    envelop Contact Supplier

    ChemTides

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aprea Reports 2nd PR for APR-1051 in ACESOT Trial
    Aprea Reports 2nd PR for APR-1051 in ACESOT Trial

    18 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/18/3240156/0/en/Aprea-Therapeutics-Announces-Additional-Positive-Clinical-Activity-for-WEE1-Inhibitor-APR-1051-Including-Second-Partial-Response-in-Ongoing-ACESOT-1051-Trial.html

    GLOBENEWSWIRE
    18 Feb 2026
    Share Share
    Aprea Therapeutics to Present at Oppenheimer Healthcare Conf
    Aprea Therapeutics to Present at Oppenheimer Healthcare Conf

    17 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/17/3239221/0/en/Aprea-Therapeutics-to-Present-at-Oppenheimer-36th-Annual-Healthcare-Life-Sciences-Conference.html

    GLOBENEWSWIRE
    17 Feb 2026
    Share Share
    Aprea Therapeutics Bolsters DDR Patents for Cancer Therapeutics
    Aprea Therapeutics Bolsters DDR Patents for Cancer Therapeutics

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237181/0/en/Aprea-Therapeutics-Strengthens-Global-Patent-Portfolio-in-DNA-Damage-Response-DDR-Cancer-Therapeutics-Paving-Way-for-Pipeline-Growth.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share
    Aprea Pharma Names Eugene Kennedy, MD, Chief Medical Advisor
    Aprea Pharma Names Eugene Kennedy, MD, Chief Medical Advisor

    04 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/04/3232041/0/en/Aprea-Therapeutics-Appoints-Industry-Veteran-Eugene-Kennedy-MD-as-Chief-Medical-Advisor.html

    GLOBENEWSWIRE
    04 Feb 2026
    Share Share
    Aprea Therapeutics Reveals Early Success In ACESOT-1051 Trial
    Aprea Therapeutics Reveals Early Success In ACESOT-1051 Trial

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228567/0/en/Aprea-Therapeutics-Announces-Early-Clinical-Proof-Of-Concept-in-the-Ongoing-ACESOT-1051-Dose-Escalation-Trial-Evaluating-WEE1-Inhibitor-APR-1051-Including-Partial-Response-Observed.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Aprea Therapeutics Announces $5.6M ATM Offering on Nasdaq
    Aprea Therapeutics Announces $5.6M ATM Offering on Nasdaq

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228563/0/en/Aprea-Therapeutics-Announces-5-6-Million-Private-Placement-Priced-At-The-Market-Under-Nasdaq-Rules.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search